Search Within

Michael Morris

  1. "Erica Dayan"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Biostatistics Service (4)
  5. Epidemiology and Biostatistics (4)
  6. Hematologic Malignancies, Division of (3)

More Groups

People
  1. Erica Dayan (6)
  2. Howard Scher (6)
  3. Daniel Danila (4)
  4. Glenn Heller (4)
  5. Karen Autio (3)
  6. Susan Slovin (3)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2017 (1)
  5. 2015 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. European Urology Oncology (1)
  3. European Urology Open Science (1)
  4. Journal of Immunotherapy and Precision Oncology (1)
  5. Urology (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Elsevier BV (2)
  3. Elsevier Science, Inc. (1)
  4. Innovative Healthcare Institute (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503)
    Journal Article

    Morris, M. J.; Mota, J. M.; Lacuna, K.; Hilden, P.; Gleave, M.; Carducci, M. A.; Saad, F.; Cohn, E. D.; Filipenko, J.; Heller, G.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer
    Journal Article

    O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Touijer, K. A.; Morris, M. J.; Danila, D. C.; Laudone, V. P.; Bochner, B. H.; Sheinfeld, J.; Dayan, E. S.; more...
    Urology (2017)

    Fulltext@MSK | Save
  • Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy
    Meeting Abstract

    Morris, M. J.; Hilden, P.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Dayan, E. S.; Filipenko, J.; Acosta, I.; Heller, G.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save